Readers are referred to the cautionary note
regarding Forward-looking Information at the end of
this release.
TSX: CNJ
WINNIPEG, April 11, 2012 /CNW/ - Cangene
Corporation today announces that Michael Graham,
its Chief Financial Officer, is leaving the
organization. This change is effective immediately.
"I would like to personally thank Mike for his
contribution to Cangene during his tenure,"
says John Sedor, President and CEO of Cangene.
"This continues organizational changes we have
made over the last six months, which include
changes to our senior management team. While
changes of this nature are sometimes difficult, the
end result is a more nimble organization that is
quick to adapt to our refocused strategy."
The Company has initiated a search for a permanent
successor to Mr. Graham and expects to fill the
position by the end of the current fiscal year. In
the interim, Mr. Sedor will serve as the Acting
Chief Financial Officer.
About Cangene Corporation
Cangene Corporation (TSX: CNJ), headquartered in
Winnipeg, Canada, is one of the nation's oldest
and largest biopharmaceutical companies and is
focused on the development and commercialization of
immune therapeutics. Cangene's products are
sold worldwide and include products that have been
accepted into the U.S. Strategic National
Stockpile. Cangene has approximately 580 employees
in six locations across North America. It operates
manufacturing facilities in Winnipeg, Manitoba and
Baltimore, Maryland (through its wholly-owned
subsidiary Cangene bioPharma, Inc.) where it
produces its own products and undertakes contract
manufacturing for a number of customers. Cangene
operates three U.S. and one Canadian
plasma-collection facilities operating under the
name Cangene Plasma Resources. For more information
about Cangene, visit the Company's website at:
www.cangene.com.
Cautionary note regarding Forward-Looking
Information
This document contains forward-looking statements
about the Corporation, including its business
operations, strategy, and expected financial
performance and condition. Forward-looking
statements include statements that are predictive
in nature, depend upon or refer to future events or
conditions, or include words such as
"expects", "anticipates",
"intends", "plans",
"will", "believes",
"estimates", or negative versions
thereof, and similar expressions. In addition, any
statement that may be made concerning future
financial performance (including revenues, earnings
or growth rates), ongoing business strategies or
prospects, future use, safety and efficacy of
unapproved products or unapproved uses of products,
and possible future action by the Corporation are
also forward-looking statements. Forward-looking
statements are based on current expectations and
projections about future events and are inherently
subject to, among other things, risks,
uncertainties and assumptions about the
Corporation, economic factors and the
biopharmaceutical industry generally. They are not
guarantees of future performance. Actual events and
results could differ materially from those
expressed or implied by forward-looking statements
made by the Corporation due to, but not limited to,
important factors such as sales levels;
fluctuations in operating results; the
Corporation's reliance on a small number of
customers including government organizations; the
demand for new products and the impact of
competitive products, service and pricing; the
availability and cost of raw materials, and in
particular, the cost, availability and antibody
concentration in plasma; progress and cost of
clinical trials; costs and possible development
delays resulting from use of legal, regulatory or
legislative strategies by the Company's
competitors; uncertainty related to intellectual
property protection and potential costs associated
with its defence as well as general economic,
political and market factors in North America and
internationally; interest and foreign exchange
rates; business competition; technological change;
changes in government action, policies or
regulations; unexpected judicial or regulatory
proceedings; catastrophic events; the
Corporation's ability to complete strategic
transactions; and other factors beyond the control
of management.
The reader is cautioned that the foregoing list of
important factors is not exhaustive and there may
be other factors listed in other filings with
securities regulators, including factors set out
under "Risk and Uncertainties" in the
Corporation's Management Discussion and
Analysis, which, along with other filings, is
available for review at www.sedar.com. The
reader is also cautioned to consider these and
other factors carefully and not to place undue
reliance on forward-looking statements. Other
than as specifically required by applicable law,
the Corporation has no intention to update any
forward-looking statements, whether as a result of
new information, future events or otherwise.
|
CANGENE CORPORATION 
By 
